Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer
January 14th 2016Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.
Watch
Dr. Jean Hoffman-Censits on the Results of a Phase II Trial Studying Atezolizumab in Bladder Cancer
January 13th 2016Hoffman-Censits says outside of the first-line therapy of cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression.
Watch
Dr. Gordon J. Freeman on Toxicities Associated With Immunotherapies
January 12th 2016Freeman says when a patient is given chemotherapy, oncologists can anticipate certain toxicities and treat accordingly. With immunotherapies, Freeman says the toxicities are associated with immune attacks where there shouldn't be any. These attacks can result in side effects such as skin rashes, colitis, and neumonitis.
Watch
Dr. Daniel Hamstra on the Noninferiority of Shorter Radiotherapy Regimens in Prostate Cancer
January 12th 2016Hamstra says that shorter regimens of radiotherapy for men whose prostates remained in tact post-surgery proved to be noninferior when compared to longer regimens. He adds that these shorter regimens are more convenient for patients, as well as more cost effective.
Watch
Padmanee Sharma discusses the constantly shifting landscape of immune response and how it differs from patient to patient. Sharma says in order to best treat a patient with bladder cancer, oncologists have to consider that immune response in patients will never be the same day to day.
Watch
Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer
January 11th 2016Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.
Watch
Dr. Oliver Sartor on the Future of Identifying Phenotypic and Genomic Heterogeneity in mCRPC
January 8th 2016Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.
Watch
Dr. Piyush Agarwal on Recognizing, Diagnosing, and Treating Penile Cancer
January 8th 2016Agarwal says patients whose penile cancer does not spread to their lymph nodes have a 95% chance of survival over the course of 5 years, while survival for those whose cancer spreads to their lymph nodes is significantly less.
Watch
Patrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.
Watch
Dr. Andrew Branagan on A New Flu Vaccine for Patients With Myeloma
January 6th 2016Branagan said in his study, which gave patients with myeloma a high-dose flu vaccine followed by a booster dose 30 days later, 66% of patients saw total serum protection from the ailment. he said previous efforts to vaccinate patients with myeloma has resulted in a 20% total serum protection.
Watch
Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma
January 6th 2016Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.
Watch
Dr. Benjamin Smith on Complication Burdens in Different Local Treatments for Breast Cancer
January 6th 2016​Benjamin Smith, MD, discusses a recent study looking at local treatments in breast cancer and the complication burdens associated with them. Smith says that any complications arising in patients with breast cancer within 2 years are strongly associated with their treatments.
Watch
Dr. Christopher Twelves on Eribulin Mesylate in Combination Therapies for Breast Cancer
January 5th 2016Twelves said historically, chemotherapy combinations have been created utilizing empirical evidence, which he says is not a sound rationale for the combinations. He adds that due to certain biological properties of eribulin mesylate, the treatment warrants further investigation as a combination therapy.
Watch
Dr. Reuben S. Harris on APOBEC3B as a Possible Treatment Variable in Breast Cancer
January 5th 2016APOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Watch
Dr. Denise Yardley on the Challenges in Treating Triple Negative Breast Cancer
December 29th 2015Denise Yardley, MD, says one of the biggest challenges the malignancy poses is triple negative breast cancer's heterogeneity, resulting in medical professionals having to rely on clinical path features that do not provide enough preciseness in treatment.
Watch
Dr. Yael Cohen on VB111 as a Potential Treatment for Ovarian Cancer
December 28th 2015Yael Cohen, MD, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.
Watch